Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746895 | 1.00 | MAPK1 (0.40) | MAPK1ATMKDM4EL3MBTL1PSMD14 | |
| SCHEMBL30505940 | 0.85 | CRBN (0.38) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL29027009 | 0.85 | CRBN (0.38) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL24401253 | 0.82 | HCAR2 (0.36) | L3MBTL1 | |
| SCHEMBL29746865 | 0.82 | HCAR2 (0.36) | L3MBTL1 | |
| SCHEMBL24401270 | 0.77 | MAPK1 (0.43) | MAPK1ATMKDM4EL3MBTL1PSMD14 | |
| SCHEMBL24401017 | 0.75 | PDK2 (0.48) | ATMKDM4ECYP3A4PDK2ALDH1A1 | |
| SCHEMBL24400676 | 0.71 | PDK2 (0.47) | MAPK1ATMKDM4ECYP3A4PDK2 | |
| SCHEMBL21186601 | 0.70 | PDK2 (0.44) | ATMKDM4ECYP3A4PDK2ALDH1A1 | |
| SCHEMBL5054886 | 0.70 | KDM4E (0.45) | MAPK1ATMKDM4EL3MBTL1PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BRAF, NRAS, RAF1 | MAPK1 899/4885ATM 1490/4885KDM4E 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.